A number of studies in developed countries have reported variation in the frequency of Epstein-Barr virus (EBV)-associated Hodgkin's disease (HD) with age. A 'three disease' model for HD that incorporates the EBV association, histological subtype of HD and age has recently been proposed. In this model, Hodgkin's disease of childhood and older adults is commonly EBV-associated and of mixed cellularity type, whereas young adult HD is generally not EBV-associated and is usually characterised by nodular sclerosis disease. A case series of HD diagnosed in the West Midlands between 1981 and 1997, inclusive, was used to investigate the applicability of the 'three disease' model. In situ hybridisation for the EBV early RNAs (EBERs) was used to determine the presence of EBV in the malignant Hodgkin/Reed-Sternberg cells. In contrast to the 'three disease' model, nodular sclerosis was the predominant subtype in each of the age groups within the case series. In addition, overall there was little variation in EBV-positive rates across the age ranges examined. However, when females were analysed separately, older women (45؉ years) were significantly more likely to have EBV-positive disease than their younger counterparts (Ͻ45 years). In summary our results do not generally support the 'three disease' model. Leukemia (2000) 14, 748-753.
Introduction
The age incidence of Hodgkin's disease (HD) is bimodal. In developed countries, the age of the first peak in incidence occurs between 15 and 34 years, and the second after 50 years of age. 1 However, in developing countries the first incidence peak tends to occur at an earlier age compared to developed countries. 2 This has led some to suggest a possible infectious aetiology for those cases of HD that account for the first peak in the incidence, with infection occurring earlier in individuals from less privileged communities. [3] [4] [5] However, there is an uneven distribution of HD subtypes within different age ranges. Mixed cellularity (MC) HD is more common in children, particularly boys, from developing communities, 2 whereas nodular sclerosis (NS) disease characterises the young adult peak in developed countries. 6 Substantial evidence has now accumulated to link the infectious agent, the Epstein-Barr virus (EBV), with the pathogenesis of HD. The relative risk of developing HD in individuals with a history of infectious mononucleosis, relative to those with no prior history, ranges between 2.0 and 5.0. 5 Additionally, elevated levels of antibodies to EBV antigens have been detected in HD patients either prior to, or at the time of diagnosis. [7] [8] [9] Evidence of an association at the cellular level was provided by the localisation of EBV DNA 10, 11 and the latent gene products, including the EBERs, 12 the Epstein-Barr nuclear antigen-1, 13 and the latent membrane proteins-1 14, 15 and -2, 16, 17 to the malignant Hodgkin and Reed-Sternberg (HRS) cells of HD. The frequency of EBV-associated HD has been shown to vary with age, [18] [19] [20] sex, 21 histological subtype, 19 country of residence 21 and ethnicity. 21 In a recent study from the UK, the frequency of EBV-associated HD was found to be higher in the age groups 0-14 years and 45+ years when compared to patients in the 15-34 or the 35-44 age groups. 18 This led the authors to propose a 'three disease' model for HD based on age and EBV status. In this model, HD of childhood (0-14 years) and older adults (45+ years) is commonly EBV-associated and of MC type, whereas young adult HD (15-34 years) is generally not EBVassociated and is usually characterised by NS disease. Although HD of young adults may also have an infectious aetiology, a study from the same group has failed to identify such an agent. 22 This study investigates the applicability of the 'three disease' model to cases of HD that have occurred in the West Midlands, UK, between 1981 and 1997 (inclusive). At the 1991 census, the West Midlands consisted of 2 551 671 residents of whom the 'White' ethnic group formed 85.4% of the population. 23 Data on the frequency of EBV-associated HD in this population by age and by the known confounders, sex and histological subtype, were analysed.
Materials and methods

Case series
Patient data (age at diagnosis and sex) and tissue samples from a case series comprising 392 cases of HD diagnosed in the West Midlands between 1981 and 1997 inclusive were collected. Searches on pathology databases within hospitals in the West Midlands were used to identify those cases that now contribute to this case series. The intention of each search was for either a complete or a representative ascertainment of cases from each hospital. In establishing this case series no selection criteria other than that the tissue blocks were paraffin-embedded, appropriately fixed, and well preserved were used.
Representativeness of the case series with that of the West Midlands Cancer Registry
The number of incident cancers of HD (ICD-10 C81) in the West Midlands between 1981 and 1996 inclusive, by age, sex and histological subtype were available from the West Midlands Cancer Registry. The histological subtypes were grouped as C81.0 (lymphocyte predominant; LP), C81.1 (NS), C81.2 (MC), C81.3 (lymphocyte depletion; LD), C81.7 (Other HD), and C81.9 (HD unspecified). 
Histological review
Haematoxylin and eosin-stained slides from all tissue blocks from the case series were prepared and the subtype determined by a single pathologist (JC) according to the REAL classification system. 24 
Detection of latent EBV infection
Four m paraffin sections were prepared, deparaffinised and washed in TBS pH 7.6. In situ hybridisation for the detection of EBERs was performed according to standard methodology. 25 Positive controls for EBER in situ hybridisation were paraffin-wax sections of lymphoblastoid cell lines grown as solid tumours in SCID mice and a known EBER-positive HD case. U6 and sense control probes were also included in all runs and their use has been previously described elsewhere. 25 Tumour specimens were recorded as either EBV-positive (EBERs detected within HRS cells) or EBV-negative (EBERs not detected in HRS cells).
Statistical methods
Analysis was by a chi-squared test with Yates' continuity correction (1 df), or a two-sided Fisher's exact test, if at least one of the expected frequencies in the 2 × 2 tables was less than five. These analyses were performed using Epi Info, Version 6.04 b, 1997. A chi-squared test (2 df) was also used to compare EBV-positive rates of HD in the age groups 15-34, 35-44, 45+ years. Differences between frequencies were deemed significant if the P value was less than 0.05.
Cases of the histological subtype LP were excluded from the analysis of the EBV-positive rate by age and sex because this disease has been shown to differ morphologically, immunophenotypically and clinically from classic HD. 24, 26, 27 The cases of HD allocated to the subtype group 'other' were also excluded from this analysis.
Age-specific EBV-positive rates standardised by sex and histological subtype were also produced. The histological subLeukemia types LP and 'other' were excluded from this standardisation and therefore the EBV-positive rate is that for the histological subtypes NS, MC and LD combined. The age-specific distribution of HD diagnosed between 1981 and 1996, by sex and histological subtype (NS, MC and LD) and registered with the West Midlands Cancer Registry was used as the age-specific standard population.
Results
Representativeness of the case series with that of the West Midlands Cancer Registry
Males were slightly more frequent in the case series (64.5%; 249/386) compared with the West Midlands Cancer Registry data (60.5%; 1214/2005), but this difference was not statistically significant (P = 0.16). The distribution of cases of HD registered with the West Midlands Cancer Registry and in the case series by age for each sex is given in Table 1 . The distribution of cases by age in the two datasets appeared to be similar, although a higher frequency of cases aged between 0 and 14 years, inclusive, in the West Midlands Cancer Registry was of borderline significance (P = 0.05). The distribution by age/sex was also similar ( Table 1) .
Cases of the histological subtype NS were more frequent in the case series (62.5%; 228/365) when compared to those cases registered with the West Midlands Cancer Registry (54.4%; 570/1047). This difference was statistically significant (P = 0.01). The absolute differences in the percentages of each of the other three subtypes between datasets were small (3% or less) and were not statistically significant. The ratio of the frequency of NS (case series to West Midlands) by sex ranged between 1.14 and 1.18, by age 1.08 and 1.17, and by age/sex 0.90 and 1.40. The ratio varied with no consistent trend and the differences were not statistically significant.
Histological subtypes
On histological review, 59.4% (233/392) of the case series were classified as NS, 16.8% (66/392) as MC, 13.5% (53/392) 24 and were described as interfollicular HD and one classified as a provisional entity according to the REAL classification.
Histological subtype by age and sex
NS was the most common subtype in both males and females. The frequency of NS disease was significantly higher in females (72.9%; 102/140) compared with males (52.0%; 131/252) (P Ͻ 0.0001). NS was also the most common subtype in each of the four age groups; 0-14 years (66.7%; 6/9), 15-34 years (73.5%; 133/181), 35-44 years (51.2%; 21/41), and 45+ years (45.3%; 73/161). This was also true when males and females were analysed separately (data from Table  2 ). Across the age groups 15-34, 35-44 and 45+ years, the percentage of NS HD appeared to decrease with advancing age. This was true for all patients and when males and females were analysed separately.
EBV-positive rate by age and sex
26.1% (83/318) of cases of HD were EBV-positive (data from Table 2 ). The frequency of EBV-positive cases was significantly higher in males (30.8%; 60/195) compared to females (18.7%; 23/123) (P = 0.02). No EBV-positive cases were found among the nine patients aged 0-14 years (Table 2 and Figure  1 ). EBV-positive rates for the other age groups were 23.5% (38/162) for the age group 15-34 years, 39.3% (11/28) for the 35-44 year olds and 28.1% (34/121) for the 45+ group. These differences were not statistically significant (P = 0.80).
In males, the EBV-positive rate peaked within the age group Comparisons of the EBV-positive rate within each subtype by sex or age were limited due to the small numbers. However, there was no evidence that the relative changes in EBVpositive rates by subtype were different between males and females. The EBV-positive rate for MC disease appeared to decrease with increasing age. Thus, in the combined age range 0-44 years the EBV-positive rate in the MC patients was 54.8% (17/31) compared to 37.1% (13/35) in the 45+ years group. However, this difference was not statistically significant (P = 0.23). Within the remaining subtype groups, NS, LD, LP or 'other', the EBV-positive rates were very similar for each of the age groups, excepting LD where each of the rates was based on a denominator of 13 cases or less. Differences in the relative variation of the male to female ratio of cases with
Figure 1
Frequency of EBV-associated Hodgkin's disease with age excluding subtypes LP and other.
age did not appear to be responsible for the differences in the relative variation in EBV-positive rates with age in the MC group compared with the subtype groupings, NS, LD, LP and 'other'.
EBV-positive rate by age: a comparison of case series
The EBV-positive rate in comparable cases of HD by age in the series of Armstrong et al 18 and this series is given in Table  3 . Our series failed to show that the frequency of EBV-associated HD was greatest in age groups 0-14 years and 45+ years, compared with 15-34 years and 35-44 years. In our series, the age group associated with the highest EBV-positive rate (35-44 years) had the lowest EBV-positive rate in the series of Armstrong et al. 18 Although the difference in the rates for this age group was not significant (P = 0.07), a statistically significant difference in EBV-positive rates between series was evident for the age group 45+ years (P Ͻ 0.001).
The EBV-positive rates for age groups 0-14, 15-34, 35-44 and 45+ years standardised by sex and subtype were 0.0%, 24.5%, 40.9% and 27.1%, respectively. Standardisation increased the difference between the age-specific EBVpositive rates in our series and that of Armstrong et al, 18 albeit only slightly.
Discussion
The sex distribution and within each sex, the age distribution, of the case series was well matched with those cases regis- Table 3 Comparison of the frequency of EBV-positive cases of Hodgkin's disease by age according to the dataset Leukemia tered with the West Midlands Cancer Registry. The significantly higher frequency of the NS subtype in our case series may be due to inter-observer variability in the classification of histological subtypes rather than a true difference. Unfortunately, the histological subtype of each case in our case series as recorded at the West Midlands Cancer Registry was not available.
Inter-observer variability is known to exist in the subtyping of HD. Based upon variation between centres in the percentage of cases assigned to the four histological subgroups of the Rye classification Sloane 28 has suggested that the biggest problem may be knowing when to assign cases to the nodular sclerosis category. In the comparison by Sloane, the percentage of NS cases ranged between 37% and 73%, although it was possible that the frequency of the various histological subtypes may have also differed slightly between centres and that this contributed to these discrepancies. In comparison the difference in the frequency of NS disease between the case series and the West Midlands Cancer Registry (62.5% vs 54.4%, respectively) appears small. However, the potential magnitude of inter-observer variability that may exist, makes comparisons between studies difficult.
Epidemiological studies of HD are infrequent and because the disease is relatively rare many studies have relied on small numbers of cases. One of the aims of this study was to assess the applicability of a recently proposed 'three disease' model for HD 18 to a case series of similar size to that used to formulate the model. This model is similar to that proposed by MacMahon. 1 However, the age group used to define the older patients in Armstrong's study 18 was 45+ years compared to 50+ years in MacMahon's study. Comparison of our series with that of Armstrong et al revealed that in both series NS was the predominant subtype within the defined disease age group 15-34 years. EBV-positive rates were also similar in this age group. This was also the age group with the most number of cases in both series (Ͼ160 cases). However, within the other age groups EBV-positive rates differed between series; in particular, we observed higher rates in the 35-44 age group and lower rates in the 45+ group. This could be expected given the low numbers of cases in each series in two of the four age groups (Ͻ30 cases). For this reason, support or refutation of a model that is based upon a similar-sized dataset is difficult. Despite this, the relatively small variation in EBVpositive rates across the age groups 15-34, 35-44 and 45+ years that we observed shows that age-specific rates, at least in our series, are more homogeneously distributed than the pronounced variation observed by Armstrong et al. 18 Differences between series in the distribution of cases by sex and histological subtype within age groups may have been responsible for some of the variation observed in the agespecific EBV-positive rates. However, by assuming that the data of Armstrong et al 18 were representative of its registry region, in terms of sex and subtype distribution within age groups, and that the regions were similarly distributed, standardisation of the EBV-positive rates by sex and subtype to the West Midlands Cancer Registry slightly increased the differences between series in the EBV-positive rates for the age groups. Variation in the ethnic composition and socio-economic variables between series may also have been responsible for some of the discrepancies observed. However, data were not available to quantify the magnitude of differences between series due to this, although it is believed to be small, or to assess representativeness of our case series, in terms of ethnic composition and socio-economic variables, to its registry region.
In our series the predominant subtype in each of the three disease age groups specified by Armstrong et al 18 (0-14, 15-34 and 45+ years) was NS. This contrasts with the 'three disease' hypothesis 18 that suggests MC HD should be the predominant subtype in the age groups 0-14 and 45+ years. The validity of subdividing the data by subtype, given the small number of cases in the 0-14 years age group (Ͻ20 cases) in each series, is debatable but the presence of NS as the predominant subtype within this age group was also found in a study by Ambinder et al. 29 It is possible that inter-observer variability in subtype classification may have been responsible for some of the differences observed in the 45+ age group, and MC was the second most frequent subtype present. However, the percentage of NS cases was approximately two-fold that of MC. The case series by Armstrong et al 18 was not subdivided by subtype. Therefore, the magnitude of any differences in the frequency of subtypes that may have existed between data series could not be assessed.
The present study is one of the largest (Ͼ300 cases) to investigate EBV positivity in HD. In common with other studies, the EBV-positive rate was higher in males. 21, 30 Comparison of the variation in the EBV-positive rate with age between different studies is difficult due to the use of different age band categories, and the histological subtypes that are included in the analysis.
In our series, for age groups between 15 and 45+ years, the EBV-positive rates did not vary significantly, and non-significant differences across different age groups have been found in other studies. 31, 32 However, subdivision of our data by sex did allow significant differences to be detected, with the EBVpositive rate in females aged 45 years or more being significantly higher than for those aged less than 45 years. This phenomenon was also observed in a study from Taiwan 30 which used the same age groups, and Glaser et al 21 found that older women with NS disease had nearly a four-fold higher EBV risk than young adult women. This age-specific protective effect in females is consistent with a role for female reproductive experience in the development of EBV-positive HD. 21 The MC histological subtype was most frequently associated with EBV and this has been found in many studies. 15, 21, 31 However, in contrast to the subtypes NS and LP, the EBVpositive rate in MC appeared to decrease with age (0-44 years vs 45+ years). Glaser et al 21 has previously reported higher EBV-positive rates in MC cases from the 40-54 year old group compared to those 55 years and older.
In conclusion, our data could not lend support to the 'three disease' model, in terms of either the variation in the frequency of EBV-associated HD with age or the variation in the predominant histological subtype with age. Although overall we observed little variation in the EBV-positive rates across the age groups, when female patients were analysed separately, the EBV-positive rate was significantly higher for females aged 45 years and above, compared to those less than 45 years.
